350 related articles for article (PubMed ID: 14645421)
1. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
2. The role of ovarian ablation in the management of breast cancer.
Wirk B
Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
[TBL] [Abstract][Full Text] [Related]
3. BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Kote-Jarai Z; Powles TJ; Mitchell G; Tidy A; Ashley S; Easton D; Assersohn L; Sodha N; Salter J; Gusterson B; Dowsett M; Eeles R
Cancer Lett; 2007 Mar; 247(2):259-65. PubMed ID: 16777318
[TBL] [Abstract][Full Text] [Related]
4. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
5. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
6. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
Nixon RM; Duffy SW
J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
[TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Eisinger F; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Julian-Reynier C; Sobol H
Int J Oncol; 2001 Jan; 18(1):5-10. PubMed ID: 11115532
[TBL] [Abstract][Full Text] [Related]
9. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
10. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
[TBL] [Abstract][Full Text] [Related]
11. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
12. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
13. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
14. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
16. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
19. Prescription of tamoxifen for breast cancer prevention by primary care physicians.
Armstrong K; Quistberg DA; Micco E; Domchek S; Guerra C
Arch Intern Med; 2006 Nov; 166(20):2260-5. PubMed ID: 17101945
[TBL] [Abstract][Full Text] [Related]
20. A comparison of bilateral breast cancers in BRCA carriers.
Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
